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Question 1
Answer: e. Anterior drooling is normal in infancy, but is considered neurodevelopmentally abnormal if it occurs in children over the age of 4 years old, and is commonly seen in those with physical, intellectual and learning disability, and poor neuromuscular coordination and oral control.
In a small randomised placebo-controlled crossover study, children with developmental delay and moderate to severe drooling received 2 weeks treatment with transdermal hyoscine. During treatment with hyoscine in what proportion of days was no drooling reported?
e. 31%
Question 3
Answer: e. In a randomised controlled trial, 11 children with developmental delay and moderate to severe drooling received two weeks of transdermal hyoscine or placebo patches, one week washout and then the other patch for two weeks. On hyoscine, the usual amount was reported on 20% of days, less than usual on 22%, much less than usual on 27% and none on 31% of days (p<0.00001).
A neurological examination is essential when assessing drooling. Which of the following should be assessed as part of the neurological examination? 
Question 5
In a placebo-controlled study more patients taking glycopyrronium solution than placebo responded as assessed by the modified 
Question 4
Answer: a. The absolute risk difference is the difference between the event rate in the experimental group and the event rate in the control group (74%−18%=56%). The NNT is the reciprocal of the absolute risk difference (1÷0.56=1.8). This means that approximately 2 patients would need to be treated with glycopyrronium oral solution instead of placebo for one to achieve at least a 3-point reduction on the modified Teacher's Drooling scale.
